Coherus Is Confident After US Ranibizumab Filing

Targeting Around 10% Share On Adalimumab

 
• By Aidan Fry
  
Generate a summary of this article
Listen to this article
Beta

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Eye
Cojerus is confident of being int he vanguard of biosimilar rivals to Roche's Lucentis ophthalmic blockbuster • Source: Shutterstock

Coherus BioSciences believes the ranibizumab biosimilar candidate for which it has licensed US commercial rights from Bioeq puts it in pole position to lead the way on rivals to Roche’s Lucentis ophthalmic brand. The US pure-play biosimilars company expects to launch at market formation in mid-2021, after the Bioeq venture between Polpharma Biologics and the Strüngmanns’ Santo Holding filed with the US Food and Drug Administration in December last year.

Bioeq’s recent FDA submission fulfils the commitment that the partners made when striking the ranibizumab licensing deal in November last...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.